Light Mode
$7.97 ↑ +0.00 (+0.00%) Trading Up from the previous close of $7.97, $0.32 below the day’s high of $8.29
-22.67 (-73.99%) / 6M
Momentum, market sentiment, and recent alerts
MPLT reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -56.5%.
No alerts for MPLT in the last day.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.